New Delhi: Serum Institute CEO Adar Poonawalla tweeted Monday to reconfirm Covishield-vaccinated Indians facing troubles with travel to the European Union – in light of the EU’s new ‘vaccine passport’ strategy not acknowledging the India-made version of the AstraZeneca-Oxford University antibody.
Mr Poonawalla stated he had “forwarded this at the highest levels… with regulators and diplomatic” and that he expects the matter would be settled soon.
“I comprehend that a lot of Indians who have obtained COVISHIELD are facing troubles with travel to the E.U., I ensure everyone, I have escalated this at the highest levels and expect to settle this issue soon, both with regulators and at a diplomatic level with nations,” he said.
The EU’s medical administrative body – the European Medicines Agency – has endorsed four vaccines, including the AstraZeneca shot developed and sold in Europe as Vaxzervria.
It has not, anyhow, sanctioned the version developed by the Serum Institute, which is retailed in India as Covishield.
Commencing July 1 the European Union schemes to initiate a ‘digital Covid certificate’ to “facilitate safe (and) free movement of citizens in the EU during the pandemic”. The ‘certificate’ is designed as proof the holder is either inoculated, holds a negative probe result or has recuperated from contamination.
Passengers from outside the EU will be necessary to hold one of these ‘certificates’ – to be acknowledged by all member-nations – that will permit restriction-free movement within the bloc.
Hence, under approved norms Indians who have been vaccinated with Covishield will not be qualified for a restriction-free travel within the European Union, and will be subject to confinement and other medical protocols imposed by each country.